Please try another search
For the six months ended 31 December 2017, Viralytics Ltd. revenues increased from A$380K to A$5.3M. Net loss increased 30% to A$9.3M. Revenues reflect R&D Tax Incentive increase from A$94K to A$5.1M. Higher net loss reflects Drug product increase from A$715K to A$4.1M (expense), Clinical trials increase of 51% to A$5.7M (expense), Unrealised foreign exchange gain decrease from A$682K (income) to A$0K.
Period Ending: | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Revenue | 5.33 | 5.96 | 0.38 | 4.5 |
Gross Profit | ||||
Operating Income | -8.95 | -4.51 | -7.81 | -2.45 |
Net Income | -9.29 | -5.16 | -7.13 | -3 |
Period Ending: | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Assets | 35.19 | 42.54 | 46.03 | 52.69 |
Total Liabilities | 4.06 | 2.95 | 2.09 | 2.36 |
Total Equity | 31.14 | 39.59 | 43.94 | 50.33 |
Period Ending: | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -11.89 | -11.41 | -7.38 | -7.54 |
Cash From Investing Activities | -0.08 | -0.12 | -0.06 | 0.02 |
Cash From Financing Activities | 0.07 | 0.34 | 0.21 | 32.72 |
Net Change in Cash | -12.25 | -11.85 | -6.55 | 24.56 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review